1Sener SF, Fremgen A, Menck HR, et al. Pancreatic cancer: a re?port of treatment and survival trends for 100 ,313 patients diagnosed from 1985-1995, using the National Cancer Database[J].J Am Coll Surg,1999,189(I) :1-7.
3Burris HA 3rd, Moore MJ, AndersenJ, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial[J].J Clin Oncol,1997 ,15(6) :2403-2413.
4Ducreux M, Rougier P, PignonJP, et al. A randomised trial com?paring 5-FU with 5-FU plus cisplatin in advanced pancreatic carci?noma[J]. Ann Oncol, 2002,13(8) :1185-1191.
5Di Costanzo F, Carlini P, Doni L, et al. Gemcitabine with or with?out continuous infusion 5 - FU in advanced pancreatic cancer: a ran?domised phase II trial of the Italian oncology group for clinical re?search (GOIRC)[J]. BrJ Cancer ,2005, 93 (2) : 185-189.
6Heinemann V, Wilke H, Mergenthaler HG, et al. Gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer[J] . Ann Oncol, 2000, 11 ( 11 ) : 1399 -1403 .
7Rocha Lima CM, Savarese D, Bruckner H, et al. lrinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer] J].J Clin Oncol ,2002, 20(5) : 1182-1191.
8Louvet C, Labianca R, Hammel P, et al. Gemcitabine in combi?nation with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial[J].J Clin Oncol, 2005 , 23 ( 15 ) : 3509-3516.
9Blomgren H, Lax I, Naslund I, et al. Stereotactic high dose frac?tion radiation therapy of extracranial tumors using an accelerator clinical experience of the first thirty-one patients[J] . Acta Oncol, 1995,34(6) :861-870.
10WongJW, Sharpe MB,Jaffray DA, et al. The use of active breathing control ( ABC) to reduce margin for breathing motion[J]. IntJ Radiat Oncol BioI Phys, 1999, 44( 4) :911-919.
